Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
基本信息
- 批准号:7691520
- 负责人:
- 金额:$ 210.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The aims of this Translational Conte Center are (1) to enhance the basic molecular and neurobiological characterization of the role of the alpha7 nicotinic acetylcholine receptor in the brain and its dysfunction in schizophrenia; (2) to use this biology to continue development of a new therapeutic strategy to improve the treatment of cognitive dysfunction and negative symptoms in persons who have schizophrenia (Project 1), and (3) to use emerging information about the developmental role of the receptor to initiate a perinatal intervention for pregnant women and their children to decrease the risk of schizophrenia (Project 2). The Center investigates the potential therapeutic effects of selective alpha 7 nicotinic agonists in animal models of neuronal dysfunction in schizophrenia and then in early human clinical trials in patients with schizophrenia.
It examines CHRNA7, the gene for this receptor, to determine how its expression becomes aberrant in
schizophrenia (Project 3) and in animal models where the gene is naturally or intentionally mutated (Project 4). It determines in humans and animal models how specific variants in the gene result in dysfunction in the development of inhibitory neuronal circuitry in the hippocampus and other forebrain regions. It then examines the effects of nicotinic agonists that can potentially alter these genetic effects on development. These agonists include selective alpha 7 nicotinic receptor agonists in animal models and nicotine itself in both humans and animal models because some pregnant women smoke cigarettes. Because the endogenous ligand during fetal brain development appears to be choline, the Center also examines the potential beneficial effects of choline supplementation on alpha 7 nicotinic receptor function and neuronal development in a clinical trial in pregnant women and their newborn infants and in related animal models. To support these investigations, the Center develops strategies to image inhibitory function hemodynamically and electrophysiologically, in both adults and infants, and it develops new animal models, including the transfer of human CHRNA7 into mice (Project 5) and models of developmental abnormalities induced by the immune response to infections (Project 6).
描述(由申请人提供):该转化中心的目的是:(1)加强α - 7烟碱乙酰胆碱受体在大脑中的作用及其在精神分裂症中的功能障碍的基本分子和神经生物学特征;(2)利用这一生物学继续发展新的治疗策略,以改善精神分裂症患者的认知功能障碍和阴性症状的治疗(项目1);(3)利用有关受体发育作用的新信息,启动孕妇及其子女的围产期干预,以降低精神分裂症的风险(项目2)。该中心研究了选择性α - 7尼古丁激动剂在精神分裂症神经元功能障碍动物模型中的潜在治疗效果,然后在精神分裂症患者的早期人类临床试验中进行了研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Freedman其他文献
Robert Freedman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Freedman', 18)}}的其他基金
Human Trial of Allosteric Modulator Alpha7 Nicotinic Receptors in Schizophrenia
变构调节剂 Alpha7 烟碱受体治疗精神分裂症的人体试验
- 批准号:
8541885 - 财政年份:2011
- 资助金额:
$ 210.25万 - 项目类别:
Human Trial of Allosteric Modulator Alpha7 Nicotinic Receptors in Schizophrenia
变构调节剂 Alpha7 烟碱受体治疗精神分裂症的人体试验
- 批准号:
8145800 - 财政年份:2011
- 资助金额:
$ 210.25万 - 项目类别:
Human Trial of Allosteric Modulator Alpha7 Nicotinic Receptors in Schizophrenia
变构调节剂 Alpha7 烟碱受体治疗精神分裂症的人体试验
- 批准号:
8336880 - 财政年份:2011
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8063248 - 财政年份:2010
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8120344 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8515784 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
相似国自然基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8063248 - 财政年份:2010
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8120344 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8515784 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8515201 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
8310139 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
精神分裂症烟碱受体的临床分子神经生物学基础
- 批准号:
7901458 - 财政年份:2009
- 资助金额:
$ 210.25万 - 项目类别:
Basic research for molecular imaging of living systems and its clinical application
生命系统分子影像基础研究及其临床应用
- 批准号:
19590206 - 财政年份:2007
- 资助金额:
$ 210.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular Neuropharmacology on histamine system : From basic to clinical investigation on unsolved issues
组胺系统的分子神经药理学:从基础到临床研究未解决的问题
- 批准号:
19390061 - 财政年份:2007
- 资助金额:
$ 210.25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research for phosphaturic factors including FGF23 as molecular targets for clinical applications.
以 FGF23 等磷酸盐因子为临床应用分子靶点的基础研究。
- 批准号:
18592001 - 财政年份:2006
- 资助金额:
$ 210.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research and clinical approach of molecular therapy for liver cirrhosis and HCC
肝硬化和肝癌分子治疗的基础研究和临床途径
- 批准号:
14370395 - 财政年份:2002
- 资助金额:
$ 210.25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




